Genelux Stock
Genelux Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Thomas D. Zindrick
- Employees
- 26
- Market cap
- $109 M
- IPO
- 26/01/2023
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed…
Genelux stock: price history
1D
-2.4%
1W
-5.5%
1M
+3.4%
6M
-13.3%
YTD
-44.5%
1Y
-54.9%
2Y
-21.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~7% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Genelux
Analyst assessment of Genelux
PRICE TARGET LOW
US$16.00
CONSENSUS
US$17.33
MEDIAN
US$16.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 20/03/2026
Genelux stock metrics
P/E
-2.72
P/B
6.75
EV/EBITDA
-3.01
RETURN ON EQUITY
-58.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.5%
FLOAT SHARES
36,435,294
AVG. DAILY VOLUME (30D)
264,110
Insider transactions (SEC)
Cappello Joseph
Zindrick Thomas
Yu Yong
Zindrick Thomas
Yu Yong
Institutional holders
Comparable stocks
Frequently asked questions about Genelux stock
What does Genelux do?
Genelux Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Thomas D. Zindrick, the company employs around 26 people.
The IPO was on 26/01/2023; the stock trades on NASDAQ under the ticker GNLX.
What do analysts say about Genelux stock?
3 analysts rate the stock, the consensus is Buy (as of 20/03/2026).
The average price target is US$17.33, ranging from US$16.00 to US$20.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Genelux report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Genelux pay a dividend?
No, Genelux currently does not pay a dividend.
Which stocks are comparable to Genelux?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Genelux stock analyzed?
Clicking "Analyze stock" lets five strategies assess Genelux against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.